Payment overview · 2025
General Payments
$52.26
3 reported records · 1 companies
Healthcare provider profile · identity verified
Edwin D Soto Gonzalez, MD
Allopathic & Osteopathic Physicians|General Practice · AGUADILLA, PR · NPI 1154383727
Verified facts
What the public records show
CMS Open Payments records show Edwin D Soto Gonzalez, MD received $52.26 in general payments during 2025 across 3 reported records.
PBG PUERTO RICO LLC accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PBG PUERTO RICO LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 738 records involving 435 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PBG PUERTO RICO LLC | Unresolved — no canonical attribution shown | $52.26 | 100.0% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $52.26 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PBG PUERTO RICO LLC | $52.26 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PBG PUERTO RICO LLC | $35.23 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PBG PUERTO RICO LLC | $17.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PBG PUERTO RICO LLC Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 738 supporting records · 435 recipient NPIs · example record 1228798592 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 444 | 135 |
| Gabapentin | Gabapentin | 421 | 104 |
| Famotidine | Famotidine | 418 | 107 |
| Metformin Hcl | Metformin Hcl | 314 | 80 |
| Losartan Potassium | Losartan Potassium | 296 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 278 | 74 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 270 | 69 |
| Omeprazole | Omeprazole | 223 | 48 |
| Simvastatin | Simvastatin | 176 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 174 | 50 |
| Diclofenac Sodium | Diclofenac Sodium | 171 | 49 |
| Glimepiride | Glimepiride | 164 | 31 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 159 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 45 |
| Synthroid | Levothyroxine Sodium | 135 | 35 |
| Farxiga | Dapagliflozin Propanediol | 134 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 41 |
| Lisinopril | Lisinopril | 123 | 33 |
| Clonazepam | Clonazepam | 122 | 18 |
| Nabumetone | Nabumetone | 120 | 32 |
| Ramipril | Ramipril | 120 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 33 |
| Carvedilol | Carvedilol | 117 | 25 |
| Enalapril Maleate | Enalapril Maleate | 114 | 30 |
| Irbesartan | Irbesartan | 114 | 30 |
| Amlodipine Besylate | Amlodipine Besylate | 113 | 41 |
| Tizanidine Hcl | Tizanidine Hcl | 109 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 29 |
| Pregabalin | Pregabalin | 106 | 12 |
| Montelukast Sodium | Montelukast Sodium | 99 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 31 |
| Alprazolam | Alprazolam | 97 | 14 |
| Alendronate Sodium | Alendronate Sodium | 95 | 25 |
| Lorazepam | Lorazepam | 94 | suppressed |
| Atenolol | Atenolol | 92 | 24 |
| Azithromycin | Azithromycin | 88 | 69 |
| Clonidine Hcl | Clonidine Hcl | 85 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 82 | 15 |
| Sertraline Hcl | Sertraline Hcl | 82 | 27 |
| Tramadol Hcl | Tramadol Hcl | 81 | 19 |
| Ketoconazole | Ketoconazole | 70 | 29 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 68 | 15 |
| Naproxen | Naproxen | 66 | 20 |
| Ezetimibe | Ezetimibe | 61 | 19 |
| Meloxicam | Meloxicam | 61 | 17 |
| Sucralfate | Sucralfate | 61 | 15 |
| Bupropion Xl | Bupropion Hcl | 60 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 60 | 12 |
| Meclizine Hcl | Meclizine Hcl | 58 | 20 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 54 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 12 |
| Baclofen | Baclofen | 48 | 11 |
| Donepezil Hcl | Donepezil Hcl | 48 | 11 |
| Ibuprofen | Ibuprofen | 47 | 18 |
| Ibandronate Sodium | Ibandronate Sodium | 46 | 12 |
| Temazepam | Temazepam | 46 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 45 | 16 |
| Glipizide | Glipizide | 45 | 13 |
| Metformin Hcl Er | Metformin Hcl | 45 | suppressed |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 45 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 12 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 40 | 14 |
| Lansoprazole | Lansoprazole | 39 | 11 |
| Trazodone Hcl | Trazodone Hcl | 38 | 13 |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 37 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Bumetanide | Bumetanide | 36 | 12 |
| Finasteride | Finasteride | 36 | suppressed |
| Latanoprost | Latanoprost | 36 | suppressed |
| Prednisone | Prednisone | 36 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Risperidone | Risperidone | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 33 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Sulindac | Sulindac | 31 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 30 | 14 |
| Eliquis | Apixaban | 30 | suppressed |
| Furosemide | Furosemide | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 25 |
| Cefadroxil | Cefadroxil | 29 | 21 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 29 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 24 |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Desonide | Desonide | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Humulin R | Insulin Regular, Human | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 14 |
| Candesartan Cilexetil | Candesartan Cilexetil | 24 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 23 | suppressed |
| Allopurinol | Allopurinol | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Sure Comfort | Syring-Needl,disp,insul,0.3 Ml | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Humalog | Insulin Lispro | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Procto-Med Hc | Hydrocortisone | 20 | suppressed |
| Sure Comfort | Syringe-Needle,insulin,0.5 Ml | 20 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 19 | 17 |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 16 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Advocate Syringes | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Sure Comfort | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 13 | suppressed |
| Leflunomide | Leflunomide | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Cilostazol | Cilostazol | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Zolmitriptan | Zolmitriptan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $52.26 · 3 records | PBG PUERTO RICO LLC | ELIQUIS, NURTEC ODT, PAXLOVID | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PBG PUERTO RICO LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error